OPKO reports Q2 net loss $10.3M; enters $250M note deal, plans $100M buyback

OPKO HEALTH, INC.

2025-Q2 EPS reported -$0.13 vs consensus -$0.11 ▼ miss (-13.5%)

Q2 total revenues $182.2M (down from $265.4M YoY); operating loss $61.7M vs income $7.0M; net loss $0.01/share.
NGENLA global launch ongoing; earned $6.3M gross profit share from Pfizer in Q2 (up from $3.8M).
Entered $250M note purchase agreement with HealthCare Royalty secured by NGENLA profit share; retains milestone upside.
Board authorized $100M share repurchase program (~10.1% of shares outstanding).
Sale of BioReference laboratory assets to Labcorp for $237.5M expected close end of Q3 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.